EUCTR2004-000383-27-SE进行中（未招募）不适用
A double-blind randomized placebo controlled crossover study of AZD7371 ER 5 mg bid, 20 mg bid and placebo treatment for one week on visceral perception and symptoms in patients with Irritable Bowel Syndrome
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Provision of written informed consent
- •2. Male or female patients aged 20-65 years
- •3. IBS patients defined by the Rome II criteria
- •4. Females of childbearing potential must use one of the following acceptable birth control methods: surgical sterilization, intrauterine device or oral contraceptives for at least 14 days prior to the first dose and throughout the study
- •5. Body Mass Index (BMI) of 19-30. Weight 55-90 kg
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Other gastrointestinal (GI) disease of importance
- •2. Clinically significant haematological, renal, hepatic, cardiovascular, neurological, mental or other serious disease
- •3. History of GI surgery except minor surgery (e.g. appendectomy, cholecystectomy or gynaecological surgery).
- •4. Any clinically significant abnormal physical findings relevant for the safety of the patient as judged by the investigator, including ECG or any clinically significant abnormal laboratory value
- •5. Positive drug screen indicating drug abuse or history of drug addiction or alcohol abuse
- •6. Pregnancy or lactation
- •7. Medications known to affect the gastrointestinal tract. If the patient uses any of the medication below or any other medication known to affect the gastrointestinal tract, these should be discontinued at least two weeks prior to visit 2: tricyclic antidepressants selective serotonin reuptake inhibitors gastrointestinal prokinetics (e.g. cisapride, metroclopramide) laxatives antidiarrhoeals antiemetics opioids anticholinergic/antispasmodic drugs analgesics mineral herb medication OTC CYP3A4 inhibitors, including, but not limited to antifungals, HIV antivirals macrolides and mifepristone CYP3A4 inducers, including but not limited to phenobarbital, phenytoin, carbamazepine and rifampin
- •8. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity
- •9. Administration of any investigational product within eight weeks preceding the first dose of the investigational product
- •10. Previous randomization in the study
- •11. Blood donation within
- •12 weeks preceding the first dose of the investigational product 12. A suspected/manifested infection according to WHO risk categories 2, 3 and 4 (see Protocol Appendix D)
- •13. Involvement in the planning and conduct of the study 14. Previous participation in more than one study with this compound 15. Inability to understand and complete the questionnaires and diary cards 16. Suspected or confirmed poor compliance.
研究者
相似试验
已完成
4 期
A study to assess the effects of Rapid Recovery on the adverse effects of alcohol consumptioACTRN12618001996257Phoenix Pharmaceuticals Pty Ltd25
进行中（未招募）
不适用
A double blind randomized placebo controlled cross-over study to validate the distinction between women with different levels of attention and valence direction for erotic stimuli, in relation with genital and subjective sexual arousal in healthy female subjects and healthy female subjects with FSD. - VAHypoactive sexual desire disorder and female sexual arousal disorderEUCTR2007-002009-31-NLEmotional Brain BV
已完成
3 期
A clinical study to evaluate the safety of cassia tora consumption in humansCTRI/2014/11/005160Director60
已完成
不适用
Clinical study to evaluate the effectiveness of A-Hango in reducing alcohol induced veisalgia symptoms in healthy adult social drinkers.CTRI/2022/04/042209Praras Bioscience Pvt Ltd76
已完成
不适用
Polypill Prevention Trial 1Circulatory SystemCardiovascular DiseaseISRCTN36672232Queen Mary University of London (UK)100